TrademarkDir
ENDURACELL
LIVE

Serial Number

79240725

Owner

Cell-Logic Pty Ltd

Filing Date

May 25, 2018

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

ENDURACELL Trademark

Serial Number: 79240725 • Registration: 5790674

ENDURACELL is a trademark filed by Cell-Logic Pty Ltd on May 25, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Cell-Logic Pty Ltd

3-5 Yorston Place

Entity Type: 03

Trademark Details

Filing Date

May 25, 2018

Registration Date

July 2, 2019

Published for Opposition

April 16, 2019

Cancellation Date

January 16, 2026

Goods & Services

Anti-bacterial pharmaceutical preparations; anti-cancer pharmaceutical preparations; meal for pharmaceutical purposes; pharmaceutical preparations for the therapeutic treatment of diabetes mellitus; pharmaceutical preparations for the treatment of alcoholism; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of cardiovascular disorders; pharmaceutical preparations for the treatment of depressive illness; pharmaceutical preparations for the treatment of dermatological disorders; pharmaceutical preparations for the treatment of digestive maladies; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of disorders of the gastro-enterological tract; pharmaceutical preparations for the treatment of gastric diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of joint related diseases; pharmaceutical preparations for the treatment of psoriasis; pharmaceutical preparations for use in the treatment of arthritis; pharmaceutical preparations for use in the treatment of hormonal disorders; pharmaceutical preparations for use in the treatment of muscle tension; pharmaceutical preparations for use in the treatment of rheumatism; pharmaceutical preparations for use in the treatment of sciatica; pharmaceutical products for combating heart diseases; pharmaceutical products for combating metabolism disorders; pharmaceutical products for the treatment of cardiovascular disorders; pharmaceutical products for the treatment of gastrointestinal disorders; pharmaceutical products for the treatment of osteoporosis

Filing History

CANCELLED SECTION 71
Jan 16, 2026 C71T
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 8, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 19, 2019 FICS
FINAL DISPOSITION PROCESSED
Oct 19, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 2, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 2, 2019 R.PR
PUBLISHED FOR OPPOSITION
Apr 16, 2019 PUBO
NOTICE OF PUBLICATION
Mar 27, 2019 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 26, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 17, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 17, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 17, 2019 TROA
REFUSAL PROCESSED BY IB
Oct 19, 2018 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 1, 2018 RFCS
REFUSAL PROCESSED BY MPU
Oct 1, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 28, 2018 RFCR
NON-FINAL ACTION WRITTEN
Sep 27, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 25, 2018 MAFR
ASSIGNED TO EXAMINER
Sep 19, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 19, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 13, 2018 REPR

Related Trademarks